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ABSTRACT
This consensus statement aimed to provide a simple 
and easily implementable practical educational guide-
line for healthcare professionals (HCPs) and patients 
regarding insulin injection practice in diabetes self-
management in the Indian setting.
A group of experts analysed published data from 
guidelines, clinical trials and real world evidence to 
reach consensus recommendations on optimal insulin 
injection practices in terms of a) the injection sites 
(preparation of site of injection, choosing the injec-
tion site, site rotation), b) choice of device and storage 
of insulins, and c) safety precautions, sharp disposal 
practice and complications.
Findings from Global and Indian arm of 2014-2015 
ITQ Study were considered to emphasize a need for 
improved practice by HCPs covering all the vital topics 
essential to proper injection habits. 
The consensus statement provides a simple and easily 
implementable practical educational guideline for HCPs 
and patients to optimize insulin injection practices in 
accordance with recent advances in device manufac-
turing, newer research findings, and updated interna-
tional guidelines as well as widespread concerns about 
neglected safety precautions such as single-patient use 
of pens and appropriate sharp disposal practices.  (Clin 
Diabetol 2019; 8, 3: 176–194)
Key words: insulin injection practices, guidelines,  
injection site, site rotation, storage, disposal, safety, 
complications
Introduction 
Insulin self-administration is an indispensable com-
ponent of diabetes management and the importance 
of guiding patients towards best injection practice 
has increasingly been recognized in accordance with 
growing awareness of the critical role of the correct 
injection technique in achieving optimal control of 
diabetes [1–7].
Incorrect selection of injection site or delivery de-
vice and inappropriate injection technique are consid-
ered to modify insulin absorption parameters, leading 
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to higher amount of insulin use and higher glycated 
haemoglobin (HbA1c) values as well as to glycaemic 
variability, unexplained hypoglycaemia and poor long-
term outcomes [8–10]. Therefore, correct insulin injec-
tion technique and correct choice of injection site and 
delivery devices have been considered as important 
as providing optimal (type and dose) insulin therapy 
in achievement of glycaemic goal in diabetes [5, 11].
Identification of patient, provider, and healthcare 
system based barriers of initiating and adhering to 
insulin injection therapy is a critical step toward suc-
cessful diabetes self-management [5, 12–16]. Optimal 
delivery and effect of all injectable agents rely on 
correct injection technique [17], emphasizing the role 
of enhanced awareness of the good injection prac-
tices among healthcare professionals (HCPs) as well 
as patients [5, 9, 18]. Several guidelines on insulin 
self-administration are available across the world as 
well as in India, whereas as consistently reported by 
several studies across the globe, there is a significant 
gap between the recommendations of the guidelines 
and actual insulin injection practice [5, 8, 10, 19–21].
Moreover, recent advances in device manufactur-
ing, newer research findings and updated international 
guidelines necessitate renewed commitment toward 
optimizing insulin injection practices [5].
Therefore, this consensus statement aimed to 
review the current guidelines and available evidence 
to provide a simple and easily implementable practical 
educational guideline on insulin injection practice for 
both HCPs and patients in terms of preparation and 
selection of injection sites, site rotation, selection of 
the device, storage of insulins, safety precautions, sharp 
disposal practice and complications.
Materials and methods
An expert panel consisting of 9 endocrinology 
specialists from university and state hospitals met to 
develop consensus on insulin injection practices in 
insulin-treated patients with diabetes in the Indian 
setting. The panel critically analysed published data 
from guidelines, clinical trials and real world evidence 
and agreed on a series of recommendations supported 
by scientific evidence and experts’ clinical opinion. The 
proposed consensus planned to provide a simple and 
easily implementable practical educational guideline for 
insulin injection practice for both HCPs and patients, 
in terms of a) the injection sites (preparation of site of 
injection, choosing the injection site, site rotation), b) 
choice of device and storage of insulins, and c) safety 
precautions, sharp disposal practice and complications 
(Figure 1).
Injection site
Injection site preparation
Current guideline recommendation on injection 
site preparation indicates the injection site should be 
clean and dry, and soap and water can therefore be 
used for unclean sites with no need for disinfection, 
whereas whenever use of alcohol swabs is needed, the 
site should be dried before injecting (Table 1) [5, 22–25]. 
However, disinfection is required in institutional set-
tings such as hospitals and nursing homes, particularly 
if the site is found to be unclean. If alcohol is used, it 
must be allowed to dry completely before the injection 
is given [26].
Consensus statement on injection  
site preparation
The expert panel recommends that the injection 
must be given to clean site using clean hands and after 
inspection and palpation, with use of soap and water 
when it is necessary to clean the site of injection. Dis-
infection of the site or the device is not recommended, 
while if alcohol swabs are used, then the area must be 
allowed to dry before the injection.
Consensus statement 1. Injection site preparation
• Injection must be given to clean site using clean hands 
• Disinfection of the site or the device is not recommended
• Cleaning of the site of injection with soap and water can 
be done 
• If alcohol swabs are used, then the area must be allowed 
to dry before the injection
• The site should be inspected and palpated by the  
individual prior to injection
Figure 1. Framework for consensus recommendations
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Choosing the injection site 
Rate of insulin absorption depends on multiple fac-
tors including insulin related factors (physicochemical 
properties, excipients, injected volume, concentration, 
and dosage) and the clinical conditions during injection 
[orthostatic position, injection site, depth of injection, 
exercises, local massage, heat exposure, smoking, 
subcutaneous tissue thickness (SCT) and subcutaneous 
adipose tissue blood flow] [27–29]. 
Overall, gender (higher risk in males), BMI (higher risk 
for < 25 kg/m2), and injection site (higher risk for thigh) 
as combined with needle length (higher risk for ≥ 8 mm) 
and insertion angle (90º), are considered to determine 
estimates of risk of intramuscular insulin injection [30–32].
Abdomen and buttock are the site of injections 
associated with fastest and slowest rates of insulin 
absorption, respectively, while lateral side of the thigh, 
not proximal to the knee, and upper arm have moderate 
absorption rates [25, 33–35].
Available guidelines on insulin injection practice 
consider abdomen as the commonest injection site 
followed by buttocks and thigh [5, 22, 23] or arm, 
[24–26] and recommend selection of thigh [5, 23, 24, 
26] and buttocks [5, 23, 26] for NPH, abdomen for 
soluble human insulin, [23, 26] abdomen (morning) 
and thigh or buttock (evening) for premixed insulins 
[23], while no specific site selection was considered for 
insulin analogues [23, 26] (Table 2).
Consensus statement on injection site selection
The expert panel recommends that abdomen (the 
site with the most consistent absorption) as followed 
by thighs and buttocks as the appropriate injection 
sites for adults, whereas the arm is not considered 
a preferred site for self-injection due to risk of intra-
muscular administration. Abdomen is considered to 
be potentially better choice of injection site for soluble 
human insulin due to characteristic fastest absorption, 
while thigh and buttocks are considered more appro-
priate for NPH injection since absorption is slowest 
from these sites. For rapid or long acting basal insulin 
analogues and GLP 1agonists, using any of the injec-
tion sites is possible as absorption rates do not appear 
to be site-specific.
Consensus statement 2. Injection site selection
• Abdomen, thighs and buttocks are the recommended 
injection sites for adults, with abdomen offering most 
consistent absorption
• The arm is not a preferred site for self-injection due to 
risk of intramuscular administration
• The thigh and buttocks may be preferred injection sites 
when using the NPH, since absorption is slowest from 
these sites
• The abdomen may be the preferred site for soluble hu-
man insulin since absorption is fastest there
Table 1. Guidelines recommendations on injection site preparation
Guideline Recommendation
Canadian Forum of Injection techniques (FIT) 
Recommendations for Best Practice in Injection 
Technique (2012) [22]
• Site should be clean and free of infection, oedema, bruising or lipohypertrophy
• Alcohol swabs may be used, but should be dried before injecting
UK FIT Recommendations for Best Practice  
in Injection Technique (2015) [23]
• Site inspection and palpation before use
• Avoid site with infection, lipohypertrophy, inflammation
• Inject in clean site with clean hands
• If unclean — use soap and water
• Disinfection usually not required; alcohol swabs may be used
American Association of Diabetes Educators 
(AADE) Strategies for Insulin Injection Therapy 
in Diabetes Self-Management (2011) [24]
• Site should be clean and dry
• Injection through single layer of clothing — clinical judgment
American Diabetes Association (ADA) Insulin 
Administration Guidelines (2004) [25]
• Wait until topical alcohol (if used) has evaporated completely before injection
Australian Diabetes Educators Association 
(ADEA) Clinical Guiding Principles for  
Subcutaneous Injection Technique (2015) [26]
• If site requires cleaning, soap and water is adequate
• Alcohol usually not required, increases skin toughening
Indian FIT Recommendations for Best Practice 
in Injection Technique (2017) [5]
• Clean site properly 
• Alcohol if used, let it evaporate, as dry surface minimizes pain
• Do not use soap-based detergent, chloroxylenol, and cetrimide/chlorhexidine
• Inject if site is considered “socially clean”
Rajeev Chawla et al., Practical guidance on insulin injection practice in diabetes self-management in the Indian setting: an expert consensus statement
179
• Rapid-acting and long acting basal insulin analogues  
may be given at any of the injection sites, as absorption 
rates do not appear to be site-specific
• When injecting rapid and long acting analogue insulin 
these should be given in different sites even if given at 
different times during the day
• Injection site showing signs of oedema, inflammation 
must be avoided
• GLP 1 agonists are absorbed equally from each of the 
usual injection sites (abdomen, arm and thigh)
Site rotation 
Correct site rotation, defined as always injecting at 
least 1 cm from a previous injection, has been consist-
ently shown to be the best way to safeguard normal 
tissue [4, 34, 36, 37].
Worldwide Injection Technique Questionnaire (ITQ) 
2014–2015 data reported that patients who rotate 
correctly tend to have lesser rates for hyperglycaemia, 
LH, unexplained hypoglycaemia and glucose variability 
[10, 38]. Incorrect rotation of sites was reported to be 
associated with 0.57% higher HbA1c levels, 4.7 IU higher 
total daily insulin dose and higher frequencies of unex-
pected hypoglycaemia and glucose variability [10, 38].
In a recent study comparing findings from 
Indian arm vs. rest of the world (ROW) in the ITQ 
2014–2015 global study, correct site rotation was 
reported to be applied by similar percentage of 
patients in the India setting (68.1%) and rest of 
the world (ROW) (71.0%), whereas much higher 
percentage of patients in India than in ROW (48.7 
vs. 18.4%) identified that they were never trained 
on correct site rotation [36].
Notably, despite its association with lower HBA1c 
levels, less LH, and more correct injection site rotation; 
routine inspection of injection sites by the HCP at least 
once a year was not met by nearly 80% of patients in 
India as well as in ROW [36, 38].
Implementation of an easy-to-follow rotation 
scheme from the onset of injection therapy is consid-
ered important in acquisition of an appropriate site 
rotation practice. One scheme with proven effective-
ness involves dividing the injection site into quadrants 
(or halves when using the thighs or buttocks), using 
one quadrant per week and moving always clockwise. 
Injections within any quadrant or half should be spaced 
at least 1 cm from each other in order to avoid repeat 
tissue trauma. Pump cannula should be placed at least 
3 cm away from previous sites. HCPs should verify that 
the rotation scheme is being followed at each visit and 
give help and advice where needed  (Figure 2, 3) [4, 
36, 39–41].
Table 2. Guideline recommendations on injection site selection
Guideline Recommendation
Canadian FIT Recommendations for Best  
Practice in Injection Technique (2012) [22]
• Abdomen, thighs and buttocks are the recommended sites 
• Abdomen — most consistent absorption
• Arm not preferred — difficult access, less SC fat and ≠ risk of IM injection
UK FIT Recommendations for Best Practice  
in Injection Technique (2015) [23]
• Thigh and buttocks — preferred for NPH
• Abdomen preferred — soluble human insulin
• Premixed insulin — abdomen (morning) and thigh or buttock (evening)
• Insulin analogues — any site
American Association of Diabetes Educators 
(AADE) Strategies for Insulin Injection Therapy 
in Diabetes Self-Management (2011) [24]
• Thigh — NPH
• Absorption fastest — abdomen > arms > thighs > buttocks
American Diabetes Association (ADA) Insulin 
Administration Guidelines (2004) [25]
• Upper arm & anterior and lateral aspects of thigh, buttocks, and abdomen  
(exception — circle with 2-inch radius around the navel)
Australian Diabetes Educators Association 
(ADEA) Clinical Guiding Principles for Subcuta-
neous Injection Technique (2015) [26]
• Abdomen — commonest site followed by buttocks, thigh and arm
• Abdomen — no injection within 5 cm of umbilicus
• Human insulin — abdomen, NPH — thigh and buttocks
• Modern analogue insulin — any site
• GLP-1 — abdomen, thigh or upper arm
Indian FIT Recommendations for Best Practice 
in Injection Technique (2017) [5]
• Indian women — discuss site beforehand, so that their sensibilities are not  
offended
• Abdomen preferred
• If risk of nocturnal hypoglycaemia with NPH — evening dose into thigh or buttock
• Buttock — for infants and toddlers, not preferred in adults
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Figure 2. Insulin injection site rotation label
Available guidelines on site rotation recommend 
teaching a structured and easy-to-follow rotation 
scheme to patients, and emphasize rotating within one 
area rather than rotating to a different area and with 
dividing the injection site into quadrants (abdomen) 
or halves (buttock or thigh), using 1 quadrant/week 
and moving clockwise and spacing injections at least 1 
cm from each other. Patient education and inspection 
at each visit is considered essential, while use of site 
rotation grids is considered useful in patients forgetting 
injection sites (Table 3) [5, 22–26, 42].
Consensus statement on site rotation
The expert panel recommends teaching an easy-
to-follow rotation scheme to patients from the onset 
of injection therapy, use of a structured rotation plan 
including one quadrant per week and moving always in 
the same direction with spacing subsequent injections 
within the quadrant at 1 cm to avoid repeated trauma 
and review and emphasize the importance of discussing 
site rotation with patient at each visit.
Consensus statement 3. Site rotation
• Individuals should be taught an easy-to-follow rotation 
scheme from the onset of injection therapy
• Structured rotation plan of  one quadrant per week  
and moving always in the same direction is proven  
and effective
• Injection within the quadrant must be spaced at 1 cm  
to avoid repeated trauma
• Site rotation at each injection is the most appropriate 
strategy for prevention of lipohypertrophy. It also  
ensures consistent absorption
• It is recommended to discuss the rotation of site with 
patient during each visit
Choice of device and storage of insulins
Selection of the device
Factors underlying the choice of right device 
include biomechanical factors (accuracy, length 
of needle, degree of dose increment and suitabil-
ity for children/visually/dexterity-challenged people), 
psychosocial factors (attractiveness, discreteness/ 
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Table 3. Guideline recommendations on site rotation
Guideline Recommendation
Canadian FIT Recommendations for Best  
Practice in Injection Technique (2012) [22]
• Teach & demonstrate “structured rotation” to patient
• Same anatomical region, same time of day, 2 to 3 cm apart injections
• Rotation of site — discuss and check at each patient visit
UK FIT Recommendations for Best Practice  
in Injection Technique (2015) [23]
• Teach easy-to-follow rotation scheme at onset of therapy
• Divide site into quadrants, 1 quadrant/week, move always in same direction 
(clockwise or anti-clockwise) 
• Space injections at least 1 cm from each other
• Teach and demonstrate for detection of lipohypertrophy
American Association of Diabetes Educators 
(AADE) Strategies for Insulin Injection Therapy 
in Diabetes Self-Management (2011) [24]
• Rotation within an area — critical for optimal absorption
• Rotation — within the same area, rather than from major site to site
• Patient education and inspection at each visit essential
American Diabetes Association (ADA) Insulin 
Administration Guidelines (2004) [25]
• Rotation — important to prevent lipohypertrophy
• Rotate within one area rather than rotating to a different area
• Helps to decrease variability in absorption from day to day
Australian Diabetes Educators Association 
(ADEA) Clinical Guiding Principles for Subcuta-
neous Injection Technique (2015) [26]
• Teach, demonstrate and document rotation in drug chart at visit
• Rotation within one area rather than into a different area
• Divide into quadrants (abdomen) or halves (buttock or thigh), 1 quadrant/week 
and move clockwise
• Site rotation grids — for pts forgetting injection sites
Indian FIT Recommendations for Best Practice 
in Injection Technique (2017) [5]
• Divide into quadrants (abdomen) or halves (buttock or thigh), use 1 quadrant/ 
/week and move clockwise
• New injection site should be at least 1–2 cm apart from the previous site
• HCPs — review site rotation scheme at least once a year
Figure 3. Ways for optimal site rotation. Adapted from Frid A. et al. Diabetes and Metabolism 2010; 36 (Suppl 2): S3–18, Kaira et 
al. Diabetes Ther. 2017; 8: 659–672. Diagrams courtesy of Lourdes Saez-de Ibarra and Ruth Gaspar, DNSPE from La Paz Hospital, 
Madrid, Spain, Spollett G. et al. The Diabetes Educator 2016; 42 (4): 379–394
Injection sites 
should be 
rotated within  
and beetwen 
regions
Thighs
Abdomen
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Arms
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/size, comfort/ease of use and ease of transport/stor-
age), environmental factors (temperature stability, 
biodegradability/“green devices”, availability of com-
patible insulins and availability of ancillary supplies), 
pragmatic factors (cost of device/insulin refills/needles, 
expected duration of insulin therapy with prescribed 
regimen and monthly dose requirement vis a vis capac-
ity of device) and medication-counselling factors (time 
taken to reach, time taken to learn, risk of error in 
delivery and availability of post-prescription follow-up).
The modern pen devices have various advantages 
over the conventional insulin delivery methods such as 
user-friendliness, comfort of injection, higher accuracy 
specially at low doses, the flexibility of incorporating 
insulin injections into a busy lifestyle which may improve 
diabetes control with much less effort, while maintaining 
the quality of life for the diabetic patients [43, 44]. Pen 
devices available in the market are summarized in Table 4. 
In a past study on the accuracy and precision of low-
dose insulin administration via various devices including 
NovoPen® (3.0 mL), BD-Mini Pen® (1.5 mL), Humalog 
Pen® (100 U/mL), 30G Precision Sure-Dose® Insulin Sy-
ringes, 30G BD Ultra-Fine II® Short Needle Syringes, and 
H-TRON-plus V100® insulin pump; the pen and pump 
devices were reported to be more accurate, and the 
pump to be more precise, than the syringes at the 1U 
and 2U doses. Syringes were considered to be danger-
ously inaccurate clinically, at the 1U dose (Figure 4) [44].
In a past study addressing dose accuracy of Novo-
Pen® 4 with respect to ISO tolerance limits [0.0–2.0 
for a target dose of 1 U, 28.5–31.5 for 30 IU and 
57.0–63.0 for 60 U, SD: ± 2.67 for each), NovoPen® 4 
was reported to be accurate before and after simulated 
lifetime use of 5475 injections in 5 years with mean 
dose of test medium delivered remained within the ISO 
tolerance limits at all doses tested and under conditions 
of mechanical and temperature stress (Figure 5) [45].
Comparison of minimum, medium, and maximum 
doses of FlexTouch® (1/40/80 U), KwikPen® (1/30/60 U) 
and SoloSTAR® (1/40/80 U) in terms of dose accuracy 
in a past study revealed that FlexTouch® delivered all 
doses consistently, as demonstrated by low standard 
deviations [46]. FlexTouch® showed similar accuracy 
to KwikPen® at 1 U and to SoloSTAR® at 40 and 80 U 
and provided equivalent accuracy at medium and 
maximum doses with all tested pens, whereas it was 
significantly more accurate at delivering 1 U of insulin 
than SoloSTAR® (Figure 6) [46].
Table 4. Available pen devices in the market
Pen Insulin types D/R Dosing 
incre-
ments
Max dose Colours/other features
Novo Nordisk
NovoPen® 4 NovoMix® 30; NovoRapid®; R 1.0 60 Silver or blue
 Levemir®; Actrapid®;
Mixtard® 30/70; Mixtard® 50/50
FlexPen® NovoMix® 30; NovoRapid®; Levemir® D 1.0 60 Blue (NovoMix®30), orange  
(NovoRapid®), green (Levemir®)
FlexTouch® Tresiba, Ryzodeg, Xultophy D 1 50 (Xultophy) 
80
Blue (Ryzodeg), green  
(Tresiba), pink (Xultophy)
Lilly
Humapen® Humalog®; Humalog® Mix 25®; Huma-
log® Mix 50®; Humulin® R; Humulin® 
NPH; Humulin® 30/70
R 1.0 60 Grey, blue, green, pink,  
red and graphiteSavvio™
Humapen® Humalog®; Humalog® Mix 25®; Huma-
log® Mix 50®; Humulin® R; Humulin® 
NPH; Humulin® 30/70
R 0.5 30 Green
Luxura HD™
Kwikpen® Humalog®; Humalog® Mix 25®; D 1.0 60 Grey
Humalog® Mix 50®
Sanofi
Solostar® Apidra®; Lantus®; Toujeo® D 1.0 80 Grey (Lantus®), blue (Apidra®), 
grey and green (Toujeo®)
AllStar™ Apidra®; Lantus® R 1.0 80 Violet
D — disposable; R — reusable
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Available guidelines consider insulin pens as the 
injection devices of choice due to shorter needle size, 
psychological advantages, convenience, accuracy and 
adherence as well as cost benefits due to treatment 
adherence (Table 5) [22–24, 26].
Consensus statement on choice of device
The expert panel recommends use of insulin pens over 
syringes for the convenience, ease of use, reduced fear of 
injections, greater treatment adherence and greater social 
acceptance. There are pen injectors dedicated to insulin 
preparations manufactured by different companies which 
may be used because they are compatible with insulin 
cartridges. However, Novo Pen® 4 and Flex Touch® are 
recommended over other devices for the ease of use, ac-
curacy and lower dose force vs. other pen devices.
Consensus statement 4. Choice of device
• Insulin pens are recommended over syringes for the con-
venience, ease of use
• Pen devices are preferred over syringes for reduced fear 
of injections and greater treatment adherence
• Pen devices are recommended over syringes as they offer 
greater social acceptance
Figure 6. Mean relative percentage difference from tar-
get dose for FlexTouch, SoloSTAR, and KwikPen. Adapted 
from Wielandt JO. et al. J Diabetes Sci Technol. 2011; 5 (5): 
1195–1199
Figure 4. Accuracy and precision of low-dose insulin administration via different devices. Adapted from Keith K. et al. Clin Pediatr 
(Phila) 2004; 43 (1): 69–74
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• Novo Pen 4 and FlexTouch  are recommended over other 
devices for the ease of use, accuracy and lower dose 
force vs other pen devices 
Storage of insulins
For optimal effect, insulin need to be stored under 
refrigerated conditions, between 2 and 8°C as main-
tained below the freezer or in the butter compartment 
of most fridges, and be protected from light when 
vials or pens are unopened [47]. However, in India, up 
to 80% patients lack a good storage facility at home, 
while even in places where refrigerators are available, 
electrical supply may be erratic [47, 48]. The insulin pen 
in use (insulin cartridge inside) can be stored at room 
temperature (15–25°C) for 30 days [49]. However, the 
room temperature in many parts of India exceeds 25°C 
especially during summer season.
A survey in India showed approximately 75% of 
insulin to be stored at cool places, while cool places 
were not defined [8]. Additionally, the median time gap 
between taking out insulin vials from refrigerator and 
insulin injection was reported to be only 5 min, which is 
considered likely to cause pain at the injection sites [8].
In another study performed in Puducherry, India, 
it was reported that storage of regular and biphasic 
insulin at 32°C and 37°C decreased the potency of 
insulin by 14 to 18% [50], emphasizing a need for pa-
tient education about the temperature and duration of 
storage of insulin vials to maintain adequate glycaemic 
control [47]. Nonetheless, improvised practical methods 
of insulin storage being implemented in rural India with 
limited facilities are as follows (Figure 7) [47].
Table 5. Guideline recommendations on choice of device
Guideline Recommendation
Canadian FIT Recommendations for Best  
Practice in Injection Technique (2012) [22]
Insulin pens are the injection devices of choice due to shorter needle size
UK FIT Recommendations for Best Practice  
in Injection Technique (2015) [23]
Pen devices may have psychological advantages over syringes and therefore maybe 
more acceptable
American Association of Diabetes Educators 
(AADE) Strategies for Insulin Injection Therapy 
in Diabetes Self-Management (2011) [24]
Cost benefits for using pens versus syringes due to improved treatment adherence
Australian Diabetes Educators Association 
(ADEA) Clinical Guiding Principles for  
Subcutaneous Injection Technique (2015) [26]
Convenience, accuracy and adherence
Figure 7. Improvised practical methods of storage in India — rural
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• Storing insulin in a small bowl of water protected 
from exposure to direct sunlight and wetting of 
the label using a water-proof tape.
• Using a small clay pot or earthenware pitcher to 
reduce an exposure to external temperature vari-
ations with insulin vial cap is not submerged, and 
the labels with insulin name, date of opening, 
and date of expiry are preserved.
• Using thermo cool boxes, with ice packs inside 
them (replaced by frozen ones on weekly basis), 
as effective refrigeration devices for insulin that 
would keep the temperature within acceptable 
limits for many days.
• Using a good insulated extra vaccination boxes 
that can keep insulin stable for many days.
• Keeping a cool wet cloth around insulin to pre-
serve insulin potency.
In fact, resource-poor mountainous areas such as 
Himalayas also pose significant challenges to insulin 
supply, storage and disposal where keeping insulin 
warm enough is an issue with temperature extremes 
range from 30°C in summer to –20°C in winter as well as 
high indoor temperature during winter since members 
of the family stay together in a single room warmed 
by an iron-framed oven [51]. Hence persons living with 
diabetes on insulin therapy report insulin storage to be 
a major challenge during winter, since they are unable 
to store their insulin vial and pens in living rooms, 
because of extreme heat, and cannot use adjoining 
rooms, as night-time temperatures routinely fall below 
freezing point [51]. Accordingly, patients are advised by 
HCPs to store insulin vials and pens by wrapping them 
in two to three layers of warm woollen cloths, made 
of sheep wool, in wooden or steel cupboards, as the 
local method of storing foodstuffs [51]. 
Manufacturer instructions on storage of insulins 
are provided in Table 6.
Consensus statement on storage of insulin
The expert panel recommends storage of inject-
able medicines in accordance with the manufacturer’s 
instructions. Insulin should be discarded if it is past 
the expiry date, is open for more than a month, is dis-
coloured or become cloudy. Insulin should be stored 
at refrigeration temperature (2–8ºC) until use, and at 
room temperature once in use, while it should never 
be frozen or exposed to extreme heat (> 30ºC) for 
prolonged periods.
Consensus statement 5. Storage of insulin
• Injectable medicines should be stored according to the 
manufacturer’s instructions
• Insulin should be discarded if it is past the expiry date 
on the bottle or if the vial has been open for more than 
a month
• If insulin is discoloured, lumps or flakes are seen, or clear 
insulin has turned cloudy, it must be discarded
• Insulin should be stored at refrigeration temperature 
(2–8ºC). Once in use, insulin may be stored at room tem-
perature
• Insulin should never be frozen or exposed to extreme 
heat (> 30ºC) for prolonged periods as this will affect 
insulin potency and alter its action
Safety precautions, disposal  
and complications
Safety precautions and sharp disposal practice 
Insulin pens are only approved for single-patient 
use and even though the needles were changed be-
tween uses, the patients were at risk due to possible 
biological contamination in the pen cartridges [52, 53]. 
In accordance with widespread concern about disease 
transmission due to repeated instances of misuse of 
insulin pens, FDA, Institute for Safe Medication Prac-
tices (ISMP), and Centres for Disease Control (CDC) 
issues similar warnings against using the same insulin 
pen to administer insulin to multiple patients [53–55].
Improper sharp disposal practices among diabetes 
patients have been considered to be as high as 80–90% 
[56, 57].
ITQ 2014–2015 Study revealed a very large number 
of used diabetes sharps to still end up in the general 
community trash with use of a container specially made 
for used sharps by only 20.7% of patients and lack of 
a past training on proper disposal of sharps in 30% 
of patients [10]. Indian arm of ITQ 2014–2015 study 
revealed that almost 65% of patients were never trained 
on proper disposal of sharps [36]. 
Nearly 3 billion injections (83% for curative purposes, 
63% in an unsafe manner) is estimated to be administered 
annually in India [58], whereas the proper way of dispos-
ing sharps is one of the important, but often neglected 
component of proper injection techniques [58–60].
Accordingly, in a KAP study on disposal of sharp 
waste in India, 84.1% of diabetic patients were reported 
to discard the sharps directly into their household waste 
bins [61]. Authors also reported that 71% patients dis-
posed at least 7 needles/week, 89% patients disposed 
at least 7 lancets/week, whereas only 14.1% diabetes 
patients received education from their HCP regarding 
proper sharp disposal [61].
This seems notable given the higher likelihood of 
improper sharp disposal practice with lack of counsel-
ling from HCPs [60], along with a wide gap between 
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translation of research findings and their implemen-
tation in practice and poor adherence to established 
guidelines for sharp disposal practice in India [60, 62].
India is home to a huge diabetic population and 
concerns over sharp disposal practices in diabetes 
self-management are therefore important and should 
not be neglected given the likelihood of outbreaks of 
blood-borne infections and related adverse health and 
economic outcomes [60].
Current guidelines on safety precautions and dis-
posal consider training of HCPs, caregivers and patients 
based on local regulations to be essential. The main rec-
ommendations include avoiding recapping, bending, 
or breaking a needle as well as disposing in household 
or public disposal system and using needle clipping 
device and puncture-resistant container (Table 7) 
[5, 22, 23, 25, 26].
Consensus statement on safety precautions 
and sharp disposal practice
The expert panel recommends single person use of 
syringes and pen needles, patient’s education about the 
safe disposal of their used sharps with reinforcement 
during subsequent visits, following local regulations 
regarding sharps disposal, avoiding disposal of sharps 
material into the public rubbish or household garbage.
Consensus statement 6. Safety precautions and sharp 
disposal practice
• Syringes and pen needles are for single person use only
• Pen devices and cartridges or vials are for single person 
use only, and must never be shared due to the risk of 
cross contamination even if the needle is changed
• Any HCP who is required to use a lifted skin fold must 
exhibit caution to avoid needle stick injury
Table 6. Manufacturer instructions on storage of insulins
Insulin Before first use After opening Shelf life
Novorapid  
(vial & penfill)
2°C–8°C up to ED Do not refrigerate, below 30°C for 4 weeks 30 months
Novomix 30 penfill 2°C–8°C up to ED Do not refrigerate, below 30°C for 4 weeks 24 months
Novomix 50 penfill 2°C–8°C up to ED Do not refrigerate, below 30°C for 4 weeks 24 months
Tresiba Flextouch 2°C–8°C up to ED Do not refrigerate, below 30°C for 8 weeks 30 months
Ryzodeg Flextouch  
& penfill
2°C–8°C up to ED Do not refrigerate, below 30°C for 4 weeks 30 months
Levemir Flexpen 2°C–8°C up to ED Do not refrigerate, below 30°C for 6 weeks 30 months
Xultophy prefilled pen 2°C–8°C up to ED Do not refrigerate, below 30°C for 21 days 24 months
Insulatard 2°C–8°C up to ED Do not refrigerate, below 25°C for 4 weeks
Actrapid 40 IU  
(vial & flexpen)
2°C–8°C up to ED Do not refrigerate, below 25°C for 4 weeks
Flexpen below 30°C for 6 weeks
Mixtard 40 IU  
(vial & flexpen)
2°C–8°C up to ED Do not refrigerate, below 25°C for 6 weeks
Flexpen below 30°C for 6 weeks
Lantus  
(vial & cartridge)
2°C–8°C up to ED 
At RT for 4 weeks
Refrigerated or RT for 4 weeks
Within pen device at RT for 4 weeks
36 months
Humalog  
(vial & cartridge)
2°C–8°C up to ED 
At RT for 4 weeks
Refrigerated or RT for 4 weeks (vial)
Cartridge at RT
36 months
Humalog Mix25,  
Mix50  
(vial & prefilled pen)
2°C–8°C up to ED 
At RT for 4 weeks (vial)
Pen at RT for 10 days
Refrigerated or RT (below 25°C) for 4 weeks (vial)
Pen at RT (below 25°C) for 10 days
36 months
Basalog 2°C–8 °C up to ED Refill at RT (below 25°C) up to 4 weeks 24 months
Apidra 2°C–8°C up to ED 
At RT for 4 weeks
Refrigerated or RT (below 25°C ) for 4 weeks
Within pen device at RT (below 25°C) for 4 weeks
Basaglar 2°C–8°C up to ED 
At RT for 4 weeks
Do not refrigerate, below 30°C for 4 weeks
Insugen 50/50  2°C–8°C up to ED 
At RT (< 25°C) for 6 weeks
Do not refrigerate, below 25°C for 42 days 36 months
Eglucent 2°C–8°C up to ED Within pen device at RT (below 30°C) for 4 weeks 36 months
Lupisulin 2°C–8°C up to ED RT (between 15°C–25°C) for 2 weeks
Insuman  
(vials & cartridge)
2°C–8°C up to ED Vails can be refrigerated or RT (below 25°C) for 4 weeks
Within pen device at RT (below 25°C) for 4 weeks
24 months
ED — expiry date; RT — room temperature
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• People with diabetes are taught about the safe disposal 
of their used sharps with reinforcement during subse-
quent visits
• Local regulations regarding sharps disposal must be fol-
lowed
• Sharps material must not be disposed of into the public 
rubbish or household garbage
• Empty pen devices can be disposed of in the normal 
household refuse when the needle is removed
Complications of insulin injections
ITQ 2014–2015 Study revealed higher rates of 
unexplained hypoglycaemia and glucose variability in 
those with LH, injecting into LH, incorrect rotation of 
sites and needle reuse [10].
According to ITQ 2014–2015 data, LH was highly 
prevalent (30.8%), while associated with consump-
tion of 10.1 IU more insulin daily, 0.55% higher HbA1c 
levels, higher rates of unexplained hypoglycaemia and 
glycaemic variability as well as with incorrect rotation 
of injection sites, use of smaller injection zones and 
reuse of pen needles [38]. 
Indian ITQ revealed 21.9% of Indian patients had 
nurse-confirmed LH with almost equivalent risk across 
sites (8.7–10.1%) except buttocks (0.0%) [36]. Inject-
ing into LH was consistently reported to be associated 
with delayed or erratic insulin absorption, potentially 
worsening the diabetes management [63, 64]. In this 
regard, it should be noted that Indian patients with LH 
were found not to inject into LH lesions as frequently 
as in ROW (35.0% vs. 56.0%), while 53% were unaware 
of the reasons underlying this practice with conveni-
ence and pain less frequently cited by Indian patients 
compared to ROW (17.0 vs. 38.0%) [36].
Although none is evidence-based, several ap-
proaches have been recommended in treatment of LH 
such as changing the insulin formulation (e.g., aspart 
to lispro, or lispro to glulisine, etc.), changing injec-
tion sites, or shifting to CSII and possibly cortisone 
injection [36].
ITQ 2014–2015 data revealed that 60.2% of pa-
tients experience bleeding and bruising (never: 50.8%, 
sometimes: 41.5%, often: 7.3%) [38]. In Indian ITQ, 
41.4% of Indian patients reported bleeding or bruising 
from their injection sites (never: 37.7%, sometimes: 
53.6%, often: 7.8%) [36].
Injection using a 4 mm needle at 90° is considered 
to deliver insulin into subcutaneous tissue for > 99.5% 
of times with minimal risk of intradermal (ID) injections. 
Majority of injections at four commonly-used sites with 
Table 7. Guidelines on safety precautions and sharp disposal practice
Guideline Recommendation
Canadian FIT Recommendations for Best  
Practice in Injection Technique (2012) [22]
• Training essential — based on local regulations
• Where available, a needle-clipping device can be used
• Needles should never be re-sheathed
UK FIT Recommendations for Best Practice  
in Injection Technique (2015) [23]
• Training of HCPs, caregivers and patients with reinforcement
• Based on local regulations
• Use needle clipping device
• Never dispose in household or public disposal system
• Pen devices without needle — can be disposed in house hold rubbish
American Association of Diabetes Educators 
(AADE) Strategies for Insulin Injection Therapy 
in Diabetes Self-Management (2011) [24]
None
American Diabetes Association (ADA) Insulin 
Administration Guidelines (2004) [25]
• Avoid recapping, bending, or breaking a needle 
• Dispose according to local regulations
• Used sharps — puncture-resistant container
Australian Diabetes Educators Association 
(ADEA) Clinical Guiding Principles for Subcuta-
neous Injection Technique (2015) [26]
• Education extremely essential on disposal and safety 
• Occupational safety
• Follow local regulations
Indian FIT Recommendations for Best Practice 
in Injection Technique (2017) [5]
• Adequate training on safety and disposal — patients and caregivers 
• Sharps containers in every ICU, ward and nursing station
• Used needles or syringes — puncture proof box/safety box/strong cardboard/ 
/glass container
• Label the box as biohazard and handover to health-care facility
• NACO guidelines — gives safe disposal methods
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a 4–5 mm needle at 90° would be delivered into the 
subcutaneous tissue with < 2% risk of intramuscular 
(IM) injections [30, 32].
When inserted 90° without pinch-up, the most 
commonly used needle worldwide (8 mm) has estimat-
ed IM risks of 25% and 9.7%, respectively, in the thigh 
and abdomen, versus 1.6% and 0.1%, respectively, with 
a 4 mm needle. A 45° insertion reduces, but does not 
eliminate, IM risk with longer needles [32].
Risk of IM injection in considered to be higher in 
arm and thigh injections and further increase with in-
creasing needle size, from 1% (4 mm) to 55% (12.7 mm, 
27% for 45°) in the arm and from 1.6% (4 mm) to 63% 
(12.7 mm, 34% for 45°) in the thigh (Table 8) [32].
ITQ 2014–2015 data revealed that pain was as-
sociated with larger needle size and needle reuse and 
increase as a function of the number of times the nee-
dle is reused [38]. Pain was commonly associated with 
bleeding, injecting through clothes, injecting insulin 
while it is still cold, LH, injecting into LH, incorrect site 
rotation, higher HbA1c levels, lower BMI, younger age, 
and higher total daily dose of insulin [38].
Indian ITQ revealed that 50% of Indian injectors 
had pain on injection [36], while authors also empha-
sized that patient awareness of injection discomfort 
depends on several factors such as needle length, 
needle diameter, injection context and apprehension 
of HCPs [36, 65, 66].
Past studies addressing injection pain reported 
no impact of injection speed (150, 300, and 450 µl/s; 
equivalent to 15–45 IU/s of U100 insulin) on pain 
[67], whereas more pain with higher injection volume 
(≥ 1200 µl or 120 IU of U100 insulin) [67–69] and 
selection of thigh compared to abdomen as an in-
jection site [67]. Nonetheless, it was concluded that 
injection pain is mild enough to be acceptable to most 
of patients particularly with today’s very thin, short 
needles [36, 67].
Current guidelines recommend regular inspection 
and palpation of sites, rotation of sites and avoiding 
needle reuse and injecting in LH to prevent LH; recom-
mend reassurance for avoid occasional bleeding and 
bruising and review of technique for frequent bleeding 
and bruising, use shorter needles and avoid IM injection 
to prevent bleeding and bruising, recommend avoid-
ing injection through clothes to prevent intradermal 
injection, avoiding 12.7 mm needles and injecting at 45 
degree and using lifted skin fold or injecting abdomen 
in slim patients to prevent IM injection; and recom-
mend injecting at room temperature, using distraction 
methods, using needles of shorter length and smaller 
diameter and a new needle at each injection, allowing 
topical alcohol (if used) to evaporate before injection, 
inserting needle in a quick smooth movement and 
injecting slowly and removing at same angle with not 
changing the direction of needle during insertion and 
withdrawal to prevent pain (Table 9) [5, 22–26].
Consensus statement on complications  
of insulin injections
For LH, the expert panel recommends patient edu-
cation about examining injection sites to detect LH and 
avoiding injection into the hypertrophic and atrophic 
areas. HCP inspection and palpation of injection sites 
at each visit, use of site rotation and non-reuse of 
needles are also recommended to prevent LH which 
should be ruled out as a cause of poor glycaemic con-
trol, hypoglycaemia and high glycaemic variability. For 
bleeding and bruising the expert panel recommends 
reassuring patients about no significant impact of oc-
casional bruising or bleeding at site on insulin action, 
whereas a review of injection technique for frequent 
Table 8. IM injection risk according to needle length and injection angle at injection sites [32]
Needle length,  
injection angle
Risk of IM injection (%)
Thigh Arm Abdomen Buttock
4 mm 90° 1.6 1.0 0.3 0.1
45° NA NA NA NA
5 mm 90° 4.7 3.1 1.1 0.5
45° NA NA NA NA
6 mm 90° 10.0 7.0 2.8 1.3
45° 2.2 1.3 0.4 0.2
8 mm 90° 25.0 19.5 9.7 5.5
45° 8.0 5.5 2.1 1.0
12.7 mm 90° 63.0 55.0 38.0 26.9
45° 34.0 27.0 14.6 8.8
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Table 9. Guideline recommendations about complications of insulin injections
Guideline Recommendation
Canadian FIT Recommendations for Best  
Practice in Injection Technique (2012) [22]
Lipohypertrophy
• Avoid injection in LH, hair roots, scars, moles and other skin abnormalities
• Use needles of shorter length and smaller diameter
• To prevent LH — site rotation, use larger injection zones, new needle
• Inspect and palpate site at each visit, patient education
• Dose reduction — if site changed from LH site to normal tissue
Bleeding and bruising
• Frequent bleeding and bruising — review injection technique
• Occasional bleeding and bruising — reassurance that won’t affect insulin action
Intradermal injection
• Avoid injection through clothes to avoid intradermal injection
IM injection
• 12.7 mm needles not recommended — risk of IM injection
• Slim patients — inject at 45° to avoid IM injection
Pain
• Inject at room temperature — to avoid pain, relax  apprehensive patient
UK FIT Recommendations for Best Practice  
in Injection Technique (2015) [23]
 
Lipohypertrophy
• Patient education, inspect site at each visit
• To prevent LH — site rotation, avoid reuse of needles
• Reduce dose — if shifting from LH to normal tissue
Bleeding and bruising
• To avoid bleeding — avoid IM injection
• Occasional bleeding and bruising — reassurance
• Frequent bleeding and bruising — review technique
Pain
• Keep injectable at room temperature
• Use needles of shorter length and smaller diameter
• Use a new needle at each injection
• Insert needle in a quick smooth movement
• Inject slowly and ensure plunger or thumb button is fully depressed
• Remove at same angle and keep hand steady
IM injection
• Use lifted skin fold in slim limbs and abdomen
American Association of Diabetes Educators 
(AADE) Strategies for Insulin Injection Therapy 
in Diabetes Self-Management (2011) [24]
 
Lipohypertrophy
• Patient education, inspect site at each visit
• To prevent LH — site rotation
Pain
• Inject at room temperature
• Allow topical alcohol (if used) to evaporate before injection
• Relax muscles at the site
• Using distraction methods
• Quickly penetrate the skin
• Don’t change direction of  needle during insertion or withdrawal
• Don’t reuse needles
• Use injection device that puts pressure on skin around the site
• Apply pressure for 5–8 seconds after injection, without rubbing, if really painful
IM injection
• Use smaller size needles
Æ
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Table 9 (cont.). Guideline recommendations about complications of insulin injections
Guideline Recommendation
American Diabetes Association (ADA) Insulin 
Administration Guidelines (2004) [25]
 
Lipohypertrophy
• To prevent LH — site rotation, avoid reuse of needles
Bleeding and bruising
• Frequent bleeding and bruising — review technique
• Apply pressure for 5–8 seconds without rubbing
• Frequent glucose monitoring
Pain
• Injecting insulin at room temperature
• Making sure no air bubbles remain in the syringe before injection
• Wait for topical alcohol (if used) to evaporate
• Keep muscles in the injection area relaxed
• Penetrating the skin quickly
• Don’t change direction of needle during insertion or withdrawal
• Don’t reuse needles
IM injection
• Use short needles specially in slim patients and children
• Inject at 45° (especially in thigh) 
Australian Diabetes Educators Association 
(ADEA) Clinical Guiding Principles for Subcuta-
neous Injection Technique (2015) [26]
 
Lipohypertrophy
• Inspect and palpate injection sites for nodules, multiple pricks over small area
• Ask about the frequency and method of site rotation and needle reuse 
• Longer diabetes duration and insulin use, frequency of injecting — higher risk of LH
• Document location and size of LH
• Rotate injection sites, use new needle
Intradermal injection
• Injection at 90° with 4 mm needle
IM injection
• Inject into the abdomen or buttocks
• Avoid sites with little SC tissue such as arms and thighs
• Use shorter needle lengths, lift skin fold, Insertion needle at 45° angle
Pain
• Injecting insulin at room temperature rather than when cold
• If using alcohol to clean the skin, injecting only after this has dried
• Use a new needle, shorter length and smaller diameter
• Penetrate skin quickly with needle and inject slowly
• Don’t change direction of needle during insertion and withdrawal
Indian FIT Recommendations for Best Practice 
in Injection Technique (2017) [5]
Lipohypertrophy
• Regular inspection and palpation of sites
• Rotation of sites, no needle reuse
• Use larger injection surface areas
• Do not inject into LH sites
• Reduce dose of insulin in habitual LH site injections if shifting to normal SC tissue
• Rule out LH — poor glycaemic control, hypoglycaemia, and high glycaemic  
variability
Bleeding and bruising
• Frequent bleeding and bruising — review injection technique
• Use shorter needles
IM injection
• Use 6 mm needles
• Avoid syringe needles in < 6 years old children and exceptionally thin adults  
(BMI < 19 kg/m2)
Pain
• Inject at room temperature, use new needles, concentrated insulin if large dose
• Neutral pH insulin if pain with acidic insulin
• Penetrate skin quickly, don’t move needle after insertion
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bruising or bleeding, and use of shorter needles for 
less frequent bleeding and bruising and consideration 
of the likelihood of IM injection for frequent bleeding 
and bruising with glycaemic variability. The expert panel 
recommends injecting into the abdomen or buttocks 
and use of shorter needle lengths, lifted skin fold and 
insertion of the needle at 45° to prevent IM injection 
and avoiding injection through clothing to prevent 
intradermal injection. For pain, the expert panel rec-
ommends considering all factors contributing to the 
perception of pain such as individual perception, needle 
length and diameter, injection technique and IM injec-
tion and recommends use of short and narrow-gauge 
(4–5-mm × 32G) insulin pen needles, injecting at room 
temperature and  allowing  topical alcohol (if used) to 
evaporate before injection, relaxing muscles at the site 
when injecting, using distraction methods, not reusing 
needles and penetrating skin quickly without chang-
ing needle direction during insertion or withdrawal to 
prevent pain. 
Consensus statement 7. Complications of insulin injections 
Lipohypertrophy
• Individuals should be taught to examine their own injection 
sites and how to detect lipohypertrophy
• Best current preventative and therapeutic strategies for 
lipohypertrophy — site rotation and non-reuse of needles
• HCP should inspect and palpate sites at each visit ideally  
in a standing position
• Avoid injection into the hypertrophic and atrophic areas
• When switching injection from areas of LH to normal  
tissue, insulin dose reduction may be required (guided  
by glucose measurement)
• Rule out LH as a cause of poor glycaemic control,  
hypoglycaemia and high glycaemic variability
Bleeding and bruising
• Reassure patients — insulin action is not affected  
by occasional bruising or bleeding at site
• Frequent bruising or bleeding — warrants a review  
of injection technique
• Less frequent bleeding and bruising — with use of shorter 
needles
• Frequent bleeding and bruising with glycaemic variability 
may point towards IM injection
IM injection
• Inject into the abdomen or buttocks
• Avoid sites with thin subcutaneous tissue such as arms  
and thighs
• Consider different techniques according to sites chosen: 
shorter needle lengths, lifted skin fold and insertion  
of the needle at 45° angle
Pain
• Factors contributing to pain — perceptual sensitivity,  
needle length and diameter, injection technique,  
and intramuscular injection
• Less pain with short and narrow-gauge (4–5-mm × 32G) 
insulin pen needles
• Inject at room temperature and allow topical alcohol  
(if used) to evaporate before injection
• Relax muscles at the site when injecting, and using  
distraction methods
• Penetrate skin quickly and don’t change needle direction 
during insertion or withdrawal
• Don’t reuse needles, and use pressure applying injection 
device around the injection site
Intradermal injections 
• Intra-dermal injection — appearance of white area when 
withdrawing needle indicates insulin has not been injected 
deeply enough
• Avoid injection through clothing to prevent intradermal 
injection
Conclusion
This expert panel based consensus statement 
provides a simple and easily implementable practical 
educational guideline for HCPs and patients to optimize 
insulin injection practices (preparation and selection of 
injection sites, site rotation, selection of device, storage 
of insulins, safety precautions, sharp disposal practice 
and complications) in accordance with recent advances 
in device manufacturing, newer research findings, and 
updated international guidelines as well as widespread 
concerns about neglected safety precautions such as 
single-patient use of pens and appropriate sharp dis-
posal practices. This seems important given the overall 
findings from ITQ studies that highlight the need of 
easy to use practical guidance to optimize insulin in-
jection practices as well as findings specific to Indian 
cohort such as suboptimal rates for patient training on 
injection practice and routine check of injection sites 
by HCPs at every visit.
Accordingly, the expert panel recommendations 
regarding insulin injection practices provided in this 
consensus statement emphasize: 
 — injecting into a clean site after inspection and pal-
pation and with use of soap and water for clean-
ing rather than disinfecting the skin; 
 — selection of abdomen (offering the most consist-
ent/fastest absorption) as followed by thighs and 
buttocks as the appropriate injection sites for 
adults, whereas potential of thigh and buttocks 
to be more appropriate for NPH due to slowest 
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absorption from these sites along with no site-
specific alterations in absorption rate of basal in-
sulin analogues;
 — teaching an easy-to-follow and structured site ro-
tation scheme to patients from the onset of injec-
tion therapy and checking injection sites routinely 
at each visit;
 — preferring use of insulin pens (particularly Novo 
Pen® 4 and Flex Touch® for dose accuracy) over 
syringes for the convenience, ease of use, reduced 
fear of injections, greater treatment adherence 
and greater social acceptance;
 — storing injectable medicines in accordance with 
the manufacturer’s instructions, with storing in-
sulin at refrigeration temperature (2–8ºC) until 
use, and at room temperature once in use by pre-
venting exposure to extreme cold or heat;
 — adhering to single person use of syringes and pen 
needles and providing patient education on safe 
sharp disposal practices per local regulations with 
avoiding disposal of sharps material into the pub-
lic rubbish or household garbage and reinforce-
ment during subsequent visits;
 — inspection and palpation of injection sites by 
HCPs at each visit to identify LH which should be 
ruled out as a cause of poor glycaemic control, 
hypoglycaemia and high glycaemic variability, 
and use of site rotation, non-reuse of needles, 
providing patient education about examining in-
jection sites to detect LH and to avoid injecting 
into the hypertrophic and atrophic areas to pre-
vent LH; reassuring patients about no significant 
effect of occasional bruising or bleeding at site 
on insulin action, whereas a review of injection 
technique, encouraging use of shorter needles 
and considering the likelihood of intramuscular 
injection and consequent glycaemic variability for 
frequent bruising or bleeding; injecting into the 
abdomen or buttocks and use of shorter needle 
lengths, lifted skin fold and insertion of the nee-
dle at 45º to prevent intramuscular injection and 
avoiding injection through clothing to prevent 
intradermal injection; considering all factors con-
tributing to the perception of pain such as indi-
vidual sensitivity, needle length and diameter, in-
jection technique and intramuscular injection, use 
of short and narrow-gauge (4–5-mm × 32G) in-
sulin pen needles, injecting at room temperature 
and allowing topical alcohol (if used) to evapo-
rate before injection, using distraction methods, 
not reusing needles and penetrating skin quickly 
without changing needle direction during inser-
tion or withdrawal to prevent pain. 
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